Company intelligence / Profile preview

Optimata

Ramat Gan, Tel Aviv District, Israeloptimata.com ↗

Ownership: Private
Development stage: Other

Overview

Optimata has demonstrated that its Virtual Patient Engine can accurately predict patient responses to oncology drugs in silico. The technology has been validated in collaborations with major pharmaceutical companies such as Novartis, Eli Lilly, and Teva Pharmaceutical Industries. In pilot studies with Eli Lilly, the system successfully predicted Phase I trial outcomes using only preclinical data. The company’s approach enables optimization of dosing regimens and patient selection before actual trials begin—potentially reducing costs and improving success rates.

Therapeutic areas: HematologyOncology
Modalities: Small moleculeBiologicDeviceNon-pharmacological therapy
Industry: Drug Discovery Services

Partnerships

NovartisEli Lilly & Co.Teva Pharmaceutical Industries Ltd.Swiss Group for Clinical Cancer Research (SAKK)

Beyond the preview

Go deeper on Optimata.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optimata.

Explore the full profile